Ozempic / GLP-1 MDLs: Open-ended Mass Tort

Patients allege Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound caused severe gastrointestinal injuries, and, in a newer companion MDL, irreversible vision loss, casting a litigation shadow over the most commercially important drug class of the decade.

LATEST DEVELOPMENT · JUN 2, 2026

Following the June 2026 NAION Science Day, the GI-injury MDL (3094) completed opening Rule 702/summary-judgment briefing on preemption, warning adequacy, and general causation, with the court setting a consolidated Rule 702 evidentiary hearing for September 10-18, 2026 ahead of bellwether selection. The NAION MDL (3163) docket grew to roughly 146 cases and held a July 2026 status conference addressing parallel state-court coordination.

PREDICTED OUTCOME

AI-GENERATED · METHODOLOGY →

Respondent win ~45% likely HORIZON: Rule 702 ruling by mid-2027 CONFIDENCE: MEDIUM

Most likely (about 45%) Novo Nordisk and Eli Lilly substantially prevail, with Judge Marston’s post-hearing Rule 702 and summary-judgment rulings in the first half of 2027 gutting MDL 3094 on warning adequacy, preemption and specific-causation grounds before any bellwether verdict, followed by a Third Circuit affirmance in 2028 or 2029. The single strongest driver is the label: delayed gastric emptying is the drugs’ intended pharmacology and was disclosed, and FDA itself vetted the 2023 ileus language, which makes a failure-to-warn theory hard to run even if general causation for gastroparesis survives on the existing epidemiology. Marston has already shown she will screen aggressively, requiring objective gastric emptying studies in August 2025, and a docket that has grown only to roughly 3,850 GI cases after three years signals a plaintiff bar that has not found the case compelling enough to scale. Defendants also have every incentive to fight rather than pay, since neither faces existential exposure and both must avoid setting a template for suing over franchises still in commercial prime. The leading alternative, at roughly 25%, is a negotiated global inventory settlement in the $300 million to $1.5 billion range once plaintiffs clear Rule 702 and win or narrowly lose one or two 2027-2028 bellwethers, with per-claim values in the $75,000 to $300,000 band. A materially mixed ruling, general causation admitted for gastroparesis and ileus but claims cut back on preemption and the NAION docket stalled at expert discovery, is the third path at roughly 20%. The small NAION MDL, still under 200 cases and a year behind on causation work, will track whatever happens in 3094 rather than drive the endgame.

Labeled, mechanistically inherent GI effects undercut failure-to-warn · Marston already imposed objective-proof gatekeeping on gastroparesis claims · Slow docket growth signals weak plaintiff-bar conviction · Defendants precedent-averse, no existential exposure, deep pockets · September 2026 Rule 702 hearing is the decisive gate

Generated by claude-opus-5 on Aug 4, 2026, from this case’s record only. It stands until a major development changes the record. Not legal or investment advice. How predictions are made →

BACKGROUND

As GLP-1 receptor agonists became the defining blockbuster drugs of the 2020s, patients began suing Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound, Trulicity), alleging the companies failed to warn that the drugs can cause gastroparesis, ileus, bowel obstruction and other severe gastrointestinal injuries. The JPML centralized the federal cases in the Eastern District of Pennsylvania in February 2024 as MDL 3094. After the death of Judge Gene E.K. Pratter, the litigation passed to Judge Karen S. Marston, who in August 2025 issued a significant gatekeeping ruling requiring gastroparesis plaintiffs to hold objective diagnostic proof, a gastric emptying study, to proceed. The docket stood at roughly 3,850 pending cases in July 2026, about three-quarters alleging gastroparesis.

The MDL is now deep in its expert phase: depositions concluded in April 2026 and Daubert and summary-judgment briefing runs through July 2026, with bellwether selection expected in the second half of the year and first trials possible in late 2026 or 2027. In December 2025, the JPML created a second, separate MDL (No. 3163, also before Judge Marston) for claims that GLP-1 drugs cause NAION, a form of sudden and irreversible vision loss. That docket, around 110 cases, held its first Science Day on June 2, 2026 ahead of expert discovery on causation. No settlements have been announced in either proceeding.

TIMELINE

SEP 2026PROCEDURAL

Rule 702 evidentiary hearing scheduled for September 10-18, 2026

Judge Marston set a consolidated Rule 702 expert-evidence hearing on warnings, preemption, and causation for September 10 through 18, 2026, to precede any bellwether trial in MDL 3094.

GLP-1 MDL 3094 Update: Ozempic Lawsuit Status July 2026 Ozempic Lawsuit | Latest Litigation News for July 2026
JUL 2026HEARING

NAION MDL holds status conference on docket and state-court coordination

Attorneys in MDL 3163 appeared before Judge Marston for a status conference covering a docket overview and a report on parallel state-court GLP-1 vision-loss litigation.

Ozempic Lawsuit | NAION | July 2026 Update
JUL 2026PROCEDURAL

Daubert and summary-judgment briefing under way in MDL 3094

Expert depositions concluded in April 2026. Dispositive and Daubert briefing extends through July, with bellwether selection expected in H2 2026 and first trials possible in late 2026 or 2027.

MDL 3094 status
JUN 2, 2026HEARING

Science Day held in NAION MDL

Both sides presented the competing science on GLP-1 drugs and NAION vision loss to Judge Marston ahead of expert discovery on causation.

Seeger Weiss NAION case update
MAY 19, 2026FILING

Opening Rule 702 and summary-judgment briefs filed in MDL 3094

Plaintiffs and defendants filed opening briefs on Rule 702 (Daubert) challenges and summary judgment covering preemption, warning adequacy, and general causation, with opposition and reply briefing continuing through the summer.

GLP-1 MDL 3094 Update: Ozempic Lawsuit Status July 2026
JAN 2026PROCEDURAL

CMO 30 sets expert-discovery and Daubert schedule

Wagstaff & Cartmell MDL 3094 update
DEC 2025FILING

JPML creates NAION vision-loss MDL 3163

Claims that GLP-1 drugs cause non-arteritic anterior ischemic optic neuropathy were centralized in a second E.D. Pa. MDL, also before Judge Marston.

Official E.D. Pa. MDL 3163 page
AUG 2025PROCEDURAL

Court requires objective proof for gastroparesis claims

Judge Marston’s gatekeeping ruling required gastroparesis plaintiffs to produce objective diagnostic evidence, a gastric emptying study, narrowing the eligible case pool.

MDL 3094 status
MAY 2024PROCEDURAL

MDL reassigned to Judge Karen S. Marston

Following the death of Judge Gene E.K. Pratter, the litigation was reassigned to Judge Marston.
FEB 2024FILING

JPML creates MDL 3094 in E.D. Pa.

Federal gastrointestinal-injury cases against Novo Nordisk and Eli Lilly were centralized in the Eastern District of Pennsylvania.

Official E.D. Pa. MDL 3094 page
AUG 2023FILING

First gastroparesis lawsuit filed

The first federal suit alleging Ozempic-related gastroparesis was filed against Novo Nordisk in Louisiana, opening the GLP-1 injury litigation.